Table 4.
Cytotoxic chemotherapies administered as first-line therapy for metastatic breast cancer (FAS)
| gBRCAm status | |||
|---|---|---|---|
| Positive (N = 33) | Negative (N = 308) | FAS (N = 341) | |
| Number of unique agents received as first-line therapy, n (%)* | |||
| 1 | 15 (45.5) | 181 (58.8) | 196 (57.5) |
| 2 | 15 (45.5) | 105 (34.1) | 120 (35.2) |
| 3 | 1 (3.0) | 16 (5.2) | 17 (5.0) |
| 4+ | 2 (6.1) | 6 (1.9) | 8 (2.3) |
| Cytotoxic chemotherapy agent (in > 5% of patients), n (%)* | |||
| Paclitaxel | 12 (36.4) | 115 (37.3) | 127 (37.2) |
| Cyclophosphamide | 5 (15.2) | 55 (17.9) | 60 (17.6) |
| Capecitabine | 7 (21.2) | 50 (16.2) | 57 (16.7) |
| Docetaxel | 6 (18.2) | 42 (13.6) | 48 (14.1) |
| Carboplatin | 5 (15.2) | 26 (8.4) | 31 (9.1) |
| Doxorubicin | 3 (9.1) | 26 (8.4) | 29 (8.5) |
| Gemcitabine | 4 (12.1) | 24 (7.8) | 28 (8.2) |
| Bevacizumab | 4 (12.1) | 22 (7.1) | 26 (7.6) |
| Cisplatin | 1 (3.0) | 22 (7.1) | 23 (6.7) |
| Epirubicin | 2 (6.1) | 19 (6.2) | 21 (6.2) |
First-line cytotoxic chemotherapy was defined as the first chemotherapy given in the metastatic setting up to disease progression. The first-line chemotherapy start date should have occurred by the time of the latest date of metastatic diagnosis being made (30 days) and informed consent being given (90 days). The window to metastatic diagnosis date was defined to capture treatments given after the initial clinical/radiologic metastatic diagnosis
BRCA breast cancer susceptibility gene, FAS full analysis set, gBRCAm germline BRCA mutation
*If an agent was reported in two or more different regimens or treatment combinations in the first line, the agent was counted only once for that patient